Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 47Breast Neoplasms 34Breast Neoplasms, Male 3Neoplasms 2Neoplasm Metastasis 2Infertility 2Advanced Breast Cancer 2Sexual Dysfunction, Physiological 1Recurrence 1Prostate Adenocarcinoma 1Primary Ovarian Insufficiency 1Osteoporosis 1Osteitis Deformans 1Leiomyoma 1Hot Flashes 1Hemorrhage 1Breast Cancer Invasive 1Anemia 1Advanced Prostate Cancer 1Advanced Metastatic Breast Cancer 1

Interventions

Fulvestrant 5Anastrozole 5Letrozole 3exemestane 2Goserelin 2ribociclib 1palbociclib 1entinostat 1elacestrant 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1RAD1901 1Paclitaxel 1Injections 1Gonadotropin-Releasing Hormone 1FCN-437c 1Everolimus 1Aromatase Inhibitors 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Advanced Breast Cancer × Goserelin × Clear all
NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
434 enrolled
Breast

Advanced Breast Cancer

NCT05438810 2022-07-05

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
312 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡